Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia

Blood

Volumn 103, Issue 6, 2004, Pages 2358-2362

  Gurrieri, Carmela ^b   Nafa, Khedoudja ^b   Merghoub, Taha ^b   Bernardi, Rosa ^b   Capodieci, Paola ^b   Biondi, Andrea ^b   Nimer, Stephen ^b   Douer, Dan ^b   Cordon Cardo, Carlos ^b   Gallagher, Robert ^b   Pandolfi, Pier Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; DNA; RETINOIC ACID;

ALLELE; APOPTOSIS; ARTICLE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; DRUG ACTIVITY; GENE DOSAGE; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PHENOTYPE; PML GENE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 12144286886     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2200     Document Type: Article

References (23)

1. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
2. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol. 2000;2:85-90.
3. Guo A, Salomoni P, Luo J, et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol. 2000;2:730-736.
4. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell. 2002;108:165-170.
5. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet. 1998;20:266-272.
6. Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 2000;406:207-210.
7. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 2000;14:2015-2027.
8. Zhong S, Delva L, Rachez C, et al. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet. 1999;23:287-295.
9. Rego EM, Wang ZG, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med. 2001;193:521-529.
10. Fogal V, Gostissa M, Sandy P, et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 2000;19:6185-6195.
11. Khan MM, Nomura T, Kim H, et al. PML-RARalpha alleviates the transcriptional repression mediated by tumor suppressor Rb. J Biol Chem. 2001;276:43491-43494.
12. Khan MM, Nomura T, Kim H, et al. Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell. 2001;7:1233-1243.
13. Alcalay M, Tomassoni L, Colombo E, et al. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol. 1998;18:1084-1093.
14. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science. 1998;279:1547-1551.
15. Ding W, Li YP, Nobile LM, et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood. 1998;92:1172-1183.
16. Zhou DC, Kim SH, Ding W, Schultz C, Warrell RPJ, Gallagher RE. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood. 2002;99:1356-1363.
17. Slack JL, Willman CL, Andersen JW, et al. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. Blood. 2000;95:398-403.
18. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996;87:308-313.
19. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998;90:1621-1625.
20. Gu BW, Xiong H, Zhou Y, et al. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proc Natl Acad Sci U S A. 2002;99:7640-7645.
21. Gallagher RE, Li YP, Rao S, et al. Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood. 1995;86:1540-1547.
22. Kogan SC, Hong SH, Shultz DE, Privalsky ML, Bishop JM. Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood. 2000;95:1541-1550.
23. Pandolfi PP. In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene. 2001;20:5726-5735.